1
rich
Libsyn
https://www.libsyn.com
90
600
VESALIUS-CV Trial: Effect of Evolocumab in Patients at CV Risk without Prior MI or Stroke
The VESALIUS‑CV trial demonstrated that adding the PCSK9 inhibitor evolocumab to optimized lipid‑lowering therapy significantly reduced the risk of first major cardiovascular events by 25% in high‑risk adults without prior heart attack or stroke and cut the risk of first heart attack by 36%. These results confirm that intensive LDL‑C lowering with evolocumab provides meaningful primary‑prevention benefits in patients with atherosclerosis or diabetes, achieving substantial event reduction over more than four years of follow‑up.  In this interview, Nanette Kass Wenger MD, MACC and Erin A. Bohula, MD, FACC discuss the VESALIUS-CV Trial: Effect of Evolocumab in Patients at CV Risk without Prior MI or Stroke. 
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
http://accelaccorg.libsyn.com/website
<iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/40043655/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe>
https://assets.libsyn.com/secure/content/198383330